文献速递肝病

2000至2020年非酒精性脂肪性肝病合并2型糖尿病患者危险因素控制与治疗趋势:一项全地区研究

Trends in risk factor control and treatment among patients with non-alcoholic fatty liver disease and type 2 diabetes between 2000 and 2020: A territory-wide study.
PubMed 文献 · Aliment Pharmacol Ther · 2023-02-23

该研究为香港全地区队列研究,纳入2000年1月1日至2021年7月31日诊断的16,084例非酒精性脂肪性肝病合并2型糖尿病成人患者。结果显示2000-2005年至2016-2020年,个体化HbA1c达标率从44.5%升至64.8%,个体化LDL-C达标率从23.3%升至54.3%,而血压控制率维持在53.1-57.2%不变。糖尿病联合治疗增加,高血压联合治疗未增加;肝硬化患者血压和LDL-C达标率更低,但他汀和二甲双胍使用不足。

要点

  • 2000-2020年,NAFLD合并T2D患者个体化HbA1c和LDL-C达标率显著提高,血压控制率无改善。
  • 肝硬化患者血压和个体化LDL-C达标率低于非肝硬化患者,但个体化HbA1c达标率更高。
  • 年轻患者(18-44岁)个体化HbA1c达标率低于中年(45-64岁)和老年(≥65岁)患者。

核心结论

  • 2000至2020年间,NAFLD合并T2D患者的血糖和血脂控制显著改善,而血压控制保持不变。

研究设计与样本

  • 全地区队列研究,纳入2000年1月1日至2021年7月31日在香港诊断的NAFLD合并T2D成人患者16,084例(平均年龄54.8±12.0岁;男性7124例[44.3%])。

主要发现

  • 个体化HbA1c达标率从2000-2005年的44.5%(95%CI 42.9-46.1)升至2016-2020年的64.8%(95%CI 64.1-65.5)。
  • 个体化LDL-C达标率从2000-2005年的23.3%(95%CI 21.9-24.7)升至2016-2020年的54.3%(95%CI 53.5-55.1)。
  • 血压控制(<140/90 mm Hg)达标率维持在53.1-57.2%不变。
  • 糖尿病联合治疗增加,尤其在血糖控制不佳者中;高血压联合治疗未见增加。
  • 肝硬化患者血压控制和个体化LDL-C达标率低于非肝硬化患者,但个体化HbA1c达标率高于非肝硬化患者;肝硬化患者二甲双胍和他汀使用不足。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: We aimed to determine the trends in risk factor control and treatment among patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2D) in 2000-2020. METHODS: We conducted a territory-wide cohort study of adult patients with NAFLD and T2D diagnosed between 1 January 2000 and 31 July 2021 in Hong Kong. T2D was defined by use of any anti-diabetic agents, laboratory tests and/or diagnosis codes. RESULTS: This study included 16,084 patients with NAFLD and T2D (mean age, 54.8 ± 12.0 years; 7124 male [44.3%]). The percentage of patients achieving individualised haemoglobin A1c (HbA1c ) targets increased from 44.5% (95% confidence interval [CI], 42.9-46.1) to 64.8% (95% CI, 64.1-65.5), and percentage of patients achieving individualised low-density lipoprotein-cholesterol (LDL-C) targets increased from 23.3% (95% CI, 21.9-24.7) to 54.3% (95% CI, 53.5-55.1) from 2000-2005 to 2016-2020, whereas percentage of patients achieving blood pressure control (<140/90 mm Hg) remained static at 53.1-57.2%. Combination therapy for diabetes increased, especially among those with poor glycaemic control, but there was no increase in combination therapy for hypertension. Fewer cirrhotic patients achieved blood pressure control and individualised LDL-C targets, but they were more likely to achieve individualised HbA1c targets than non-cirrhotics. Metformin and statins were underused in cirrhotic patients. Younger patients (18-44 years) were less likely to achieve individualised HbA1c targets than middle-aged (45-64 years) and older ones (≥65 years). CONCLUSIONS: From 2000 to 2020, glycaemic and lipid control improved significantly, whereas blood pressure control remained static among patients with NAFLD and T2D.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Zhang X, Yip TC, Tse YK, et al. Trends in risk factor control and treatment among patients with non-alcoholic fatty liver disease and type 2 diabetes between 2000 and 2020: A territory-wide study. Aliment Pharmacol Ther. 2023. PMID: 36815548. doi:10.1111/apt.17428

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。